NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA422

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA422

1.1 Crizotinib is recommended, within its marketing authorisation, as an option for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults. The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta422

Site by Devopa
© Copyright 2019 NHS. All rights reserved.